828-25-1

Usage

Uses

Used in Organic Synthesis:
(+/-)-3-(4-iodophenoxy)-1,2-epoxypropane is used as a building block in organic synthesis for the creation of more complex molecules. Its unique structure allows it to participate in various chemical reactions, making it a versatile component in the synthesis of pharmaceuticals, agrochemicals, and other organic compounds.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (+/-)-3-(4-iodophenoxy)-1,2-epoxypropane is used as a reagent in the development of new drugs. Its structure enables it to be involved in ring-opening reactions and nucleophilic substitutions, which are essential processes in the synthesis of medicinal compounds.
Used in Agrochemical Industry:
(+/-)-3-(4-iodophenoxy)-1,2-epoxypropane also finds applications in the agrochemical industry, where it is used in the synthesis of pesticides and other agricultural chemicals. Its unique properties, such as the presence of the 4-iodophenoxy group, make it a valuable component in the development of effective and targeted agrochemicals.
Used in Research and Industrial Processes:
Due to its potential applications and structural features, (+/-)-3-(4-iodophenoxy)-1,2-epoxypropane is utilized in research and industrial processes. It serves as a valuable tool for scientists and researchers to explore new chemical reactions and develop innovative products in various fields.

Upstream product

• 540-38-5 p-Iodophenol 
• 106-89-8 epichlorohydrin 
• 118712-54-2 glycidyl p-toluenesulfonate 
• 3132-64-7 1,2-Epoxy-3-bromopropane 

Downstream Products

• 65854-89-9 1-(p-iodophenoxy)-3-isopropylamino-2-propanol 
• 1263187-98-9 1-(2-chloro-4-nitro-1H-imidazol-1-yl)-3-(4-iodophenoxy)propan-2-ol 
• 1263187-99-0 2-[(4-iodophenoxy)methyl]-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-17-2 2-{[(4'-fluoro[1,1'-biphenyl]-4-yl)oxy]methyl}-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-18-3 6-nitro-2-({[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]oxy}methyl)-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1263187-19-4 6-nitro-2-({[4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]oxy}methyl)-2,3-dihydroimidazo[2,1-b][1,3]oxazole 
• 1253834-16-0 2-((4-iodophenoxy)methyl)thiirane 
• 302781-47-1 (+/-)-1-(N-benzyl)tert-butylamino-3-(4-iodophenoxy)propan-2-ol 
• 302781-44-8 (+/-)-1-tert-butylamino-3-(4-iodophenoxy)propan-2-ol 

Relevant academic research and scientific papers

Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis

6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole derivatives were initially studied for tuberculosis within a backup program for the clinical trial agent pretomanid (PA-824). Phenotypic screening of representative examples against kinetoplastid diseases unexpectedly led to the identification of DNDI-VL-2098 as a potential first-in-class drug candidate for visceral leishmaniasis (VL). Additional work was then conducted to delineate its essential structural features, aiming to improve solubility and safety without compromising activity against VL. While the 4-nitroimidazole portion was specifically required, several modifications to the aryloxy side chain were well-tolerated e.g., exchange of the linking oxygen for nitrogen (or piperazine), biaryl extension, and replacement of phenyl rings by pyridine. Several less lipophilic analogues displayed improved aqueous solubility, particularly at low pH, although stability toward liver microsomes was highly variable. Upon evaluation in a mouse model of acute Leishmania donovani infection, one phenylpyridine derivative (37) stood out, providing efficacy surpassing that of the original preclinical lead.

NITROIMIDAZOOXAZINE AND NITROIMIDAZOOXAZOLE ANALOGUES AND THEIR USES

The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.

Determination of the enantiomeric purity and the configuration of β- aminoalcohols using (R)-2-fluorophenylacetic acid (AFPA) and fluorine-19 NMR: Application to β-blockers

A method has been developed for determining the enantiomeric purity and the absolute configuration of β-aminoalcohols of type ArOCH2CH(OH)CH2NHR (R = iPr, tBu). To determine enantiomeric purity, the amine function was first protected by a benzyl group, then the compound formed was esterified using the acid chloride of (R)-2-fluorophenylacetic acid (AFPA). The 19F NMR analysis of the derivative obtained revealed the presence of two distinctly separate signals (~2.5 ppm), the one for the RS-SR pair being the most deshielded. The configuration was determined directly on the aminoalcohol by using the acid. In stoichiometric conditions, when R = iPr, the amide function was obtained very preponderantly. The 19F NMR spectrum of the amide presented four distinct signals when derivatization was carried out by means of a reaction between the (±)-β-aminoalcohol and the (R)-AFPA. The extreme signals, which were over 3.5 ppm apart, did not belong to the same diastereomer. With R = tBu essentially the ester function was obtained. The first studies revealed the presence of two signals, though not as clearly separated as in the previous cases. Each experiment was simple to perform, and purification was not necessary. Mosher's acid gave unsatisfactory results in each case. (C) 2000 Elsevier Science Ltd.

Potential organ- or tumor-imaging agents XIX: Radioiodinated antiarrhythmic drugs as potential myocardial imaging agents

Iodinated and radioiodinated analogs of propranolol and N,N-dimethylpropranolol were synthesized wherein an iodophenyl moiety replaced the naphthalene ring of the parent drug. These new compounds were evaluated not only for their β-adrenergic blocking and